Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9775	Companies
195653	Keywords
126663	Articles
104024	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/01/2025 at 07:05, 4 months 29 days ago

Biophytis Announces Phase 2 Obesity Trial with BIO101

Biophytis Phase 2 Trial BIO101 Obesity Muscle Wasting
REGULATED PRESS RELEASE

published on 09/01/2025 at 07:00, 4 months 29 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis reveals Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting in obese patients. Expanding therapeutic horizons and commercial prospects

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
PRESS RELEASE

published on 09/01/2025 at 06:59, 4 months 29 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis unveils Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting associated with obesity. The new program broadens potential and value-creation opportunities globally

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
BRIEF

published on 08/28/2025 at 07:05, 5 months 2 days ago

Biophytis Gains Regulatory Approval for Phase 3 Sarcopenia Trial

Biophytis Regulatory Approval Clinical Trial Sarcopenia Phase 3
REGULATED PRESS RELEASE

published on 08/28/2025 at 07:00, 5 months 2 days ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, marking a significant milestone in developing therapies for muscle loss in aging individuals

Biophytis Sarcopenia Phase 3 EMA Belgian Regulatory Approval
PRESS RELEASE

published on 08/28/2025 at 06:59, 5 months 2 days ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, enabling patient enrolment in Belgium and collaboration with European centers

Biophytis Sarcopenia Phase 3 EMA Approval Belgian Regulatory Approval
BRIEF

published on 08/05/2025 at 23:05, 5 months 24 days ago

Biophytis Secures €1 Million Non-Dilutive Bond Financing

Biophytis Bond Financing Shareholder Impact Non-dilutive OBA101 Program
REGULATED PRESS RELEASE

published on 08/05/2025 at 23:00, 5 months 24 days ago

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million
Biophytis secures a non-dilutive bond financing line of up to €1 million with Hexagon Capital Fund to support OBA101 program development and strengthen cash position

Biophytis Financing Hexagon Capital Fund OBA101 Program Non-dilutive Bond
PRESS RELEASE

published on 08/05/2025 at 22:59, 5 months 24 days ago

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million
Biophytis secures a non-dilutive bond financing line of up to €1 million from Hexagon Capital Fund. The bonds, with 12% annual interest rate, will mature in 24 months and may be repaid in shares

Biophytis Hexagon Capital Fund Non-dilutive Bond Financing 12% Interest Rate Repayment In Shares
BRIEF

published on 07/30/2025 at 07:05, 6 months ago

Biophytis Joins Silver Innov' to Boost Silver Economy Initiatives

Biophytis Healthcare Innovation Longevity Sarcopenia Silver Innov'

Accesswire

Published on 01/30/2026 at 14:00, 3 hours 47 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 9 hours 12 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 9 hours 47 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 15 hours 32 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 17 hours 47 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 17:29, 18 minutes ago

EQS-Adhoc: The Payments Group Holding GmbH & Co. KGaA: The Payments Group Holding – Successful issuance of convertible bond
Published on 01/30/2026 at 17:09, 38 minutes ago

Halfords Group PLC: Total Voting Rights
Published on 01/30/2026 at 16:54, 53 minutes ago

Holding(s) in Company
Published on 01/30/2026 at 16:46, 1 hour 1 minute ago

Custodian Property Income REIT plc: Investor Presentation via Investor Meet Company
Published on 01/30/2026 at 16:00, 1 hour 47 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation

Les Echos

Published on 01/30/2026 at 17:45, 2 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 9 hours 47 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 23 hours 47 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE